FDA issued a complete response letter for UX111, and Bank of America reiterated a Buy rating for Ultragenyx Pharmaceutical.
2 reports, 2 independent
Updated Aug 9
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA issued a complete response letter for UX111, and Bank of America reiterated a Buy rating for Ultragenyx Pharmaceutical.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Ultragenyx Pharmaceutical
biopharmaceutical company based in Novato, California, United States
Related events
- Argenx SE announced it is listed on Nasdaq and is seeking FDA priority review and approval.
- ADC Therapeutics received accelerated approval for its drug from the FDA.
- NRx Pharmaceuticals is seeking regulatory approval from the FDA for its drug candidates, NRX-100 and NRX-101.
- Benchmark and Jefferies reaffirmed buy ratings while the FDA cited toxicity findings for Bright Minds Biosciences Inc.
Coverage
Newest first; wire copies grouped- yahoo.com
- Insider MonkeyBank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE) Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the Best 52-Week Low Stocks to Buy According to Analysts.